Dresden 2026 – scientific programme
Parts | Days | Selection | Search | Updates | Downloads | Help
BP: Fachverband Biologische Physik
BP 27: Cell Mechanics I
BP 27.8: Talk
Thursday, March 12, 2026, 11:45–12:00, BAR/0205
Intracellular ROS generation under ultra-high dose rate electron irradiation at FLASHlab@PITZ — •Y. Komar1,2,3, E. Fujan2, C Richard1, X. Li1, N. Aftab1, A. Aksoy1, Z. Amirkhanyan1, A. Chiravuri1,2, J. Good1, M. Gross1, F. Hausmann3, S. Khammee1, M. Krasilnikov1, B. Li1, Z. Lotfi1, G. Montoya-Soto1, F. Müller1, A. Oppelt1, F. Riemer1, K. Suzart1, E. Tarakci1,2,3, I. Tinhofer3, D. Villani1, S. Worm1, D. Xu1, S. Zeeshan1, M. Frohme2, F. Stephan1, S. Aminzadeh1,2, and A. Grebinyk1,2 — 1Deutsches Elektronen-Synchrotron, Zeuthen, Germany — 2Technical University of Applied Sciences Wildau, Wildau, Germany — 3Charité University Medicine Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
The new FLASHlab@PITZ beamline commissioning started in August 2025 for radiobiological studies at the Photo-Injector Test Facility at DESY in Zeuthen (PITZ). It enables irradiation with dose rates ranging from conventional (CDR, 0.05Gy/s) up to ultra-high (UHDR, 10^14Gy/s). The in vitro effects of UHDR versus CDR irradiation were examined using human lung cancer A549 and healthy HEL299 cells exposed to CDR (0.05Gy/s) and UHDR (7.8*10^5Gy/s). Reactive oxygen species production assessment showed 84% decrease in HEL299 cells and no difference in A549 at ~7.5Gy under UHDR compared with CDR. That indicates UHDR irradiation having a milder impact on healthy than on cancer cells, highlighting the potential of FLASHlab@PITZ for future in vivo studies.
Keywords: Radiation therapy; Cancer; in vitro; Ultra-high dose rate; Reactive oxygen species